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 Ambient ionization mass spectrometry (AIMS) is a category of mass spectrometry (MS) 
techniques originally characterized as using ambient ionization sources to analyze samples with 
little to no sample preparation and no chromatography step. This set of techniques have quickly 
gained popularity due to fast workflows and the ability to perform high throughput analysis. 
However, AIMS is prone to high matrix effects and reduced sensitivities. Solid-phase 
microextraction (SPME) is commonly used to mitigate these effects due to easy integration into 
pre-existing AIMS workflows, enabling preconcentration and extraction. Probe electrospray 
ionization (PESI) is a technique developed by Hiraoka and colleagues in 2007, then 
commercialized by Shimadzu Corporation years later. In PESI a small metal probe is dipped into 
the sample and immediately moved upwards, close to the inlet of a mass spectrometer to facilitate 
electrospray ionization (ESI). In recent years there has been a shift from using PESI for qualitative 
studies towards quantitative studies. With this shift in intentions, sample preparation has been 
incorporated into PESI workflows. The objective of this work is to incorporate SPME as a sample 
preparation method for PESI and develop applications for this technique. The first objective was 
to see if the PESI probes could be coated and to see if SPME-PESI-MS/MS could give reliable 
MS data. To ensure reproducibility of such small probes, intra- and inter-probe reproducibility 
tests by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) were 
conducted using drugs of abuse. These results show reproducibility of the probes with almost all 
relative standard deviations being ≤ 15%. Afterward, the optimal desorption solution for SPME-
PESI-MS/MS was determined. It was also found that a coated PESI probe used for SPME-PESI-
MS/MS could not be used for a subsequent LC-MS/MS run without extracting the sample again 
due to significant desorption by SPME-PESI-MS/MS. Furthermore, an application of SPME-
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PESI-MS/MS to quantitate drugs of abuse from 30µL of plasma was developed. The intra-day 
precision of said method was under 15% for all compounds. The inter-day precision of all 
compounds was under 15% except for lorazepam at the 30 ng mL-1 validation point and oxazepam 
at the 90 ng mL-1 validation point. The accuracy of all compounds for this method was within 80-
120% except for lorazepam at the 30 ng mL-1 validation point. The small dimensions of the coated 
PESI probes were then leveraged to determine the free concentration and plasma protein binding 
of diazepam from human plasma by SPME-PESI-MS/MS. The plasma protein binding determined 
by SPME-PESI-MS/MS was 99.3% which falls within literature values of 97-99% from human 
plasma samples spiked with 25 ng mL-1 of diazepam. Finally, the development of a screening 
method for aminoglycosides was explored with SPME-PESI-MS/MS. This was to explore the use 
of AIMS technologies as an alternative screening method for compounds that require conditions 
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Chapter 1 Introduction 
1.1 Ambient Ionization Mass Spectrometry (AIMS) 
 
In an analytical chemistry workflow, there are generally five major components that must be 
performed in sequential order: sampling, sample preparation, separation, detection, and data 
processing & interpretation. Generally, sample preparation is the most time consuming of the five 
steps with up to 80% of researchers’ time spent on this step.2 Depending on the application, the 
sensitivity and selectivity provided by these workflows may not justify the time taken.  Minimizing 
or removing the sample preparation and separation steps leads to dramatically decreasing the time 
spent in an analytical workflow. 
Ambient Ionization Mass Spectrometry (AIMS) is a category of mass spectrometry techniques 
which generate ions from samples under ambient conditions with little to no sample preparation 
and no chromatographic separation.1 AIMS has been enabled by the development and 
popularization of ambient ionization techniques such as electrospray ionization (ESI), atmospheric 
pressure chemical ionization, and laser desorption. The lack of chromatography found in AIMS 
techniques allow for quick and high throughput analysis of samples when compared to traditional 
mass spectrometry methods that involve chromatography before MS.3 This can be leveraged to 
bring rapid, real-time and relatively cheap analysis of samples on-site or in the laboratory. The 
number of AIMS techniques has increased rapidly from the term’s inception when Takats et al. 
first published desorption electrospray ionization (DESI) in 2004.4 AIMS is a rapidly growing field 
of mass spectrometry in both its adoption and the development of new techniques. 
AIMS can be sorted into three categories based on desorption and ionization strategies 
proposed by Huang et al. in 2011: (1) direct ionization, (2) direct desorption/ionization, and (3) 
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two-step ionization.1 Direct ionization techniques ionize analytes directly from liquid samples or 
droplets of the liquid sample.1 Techniques that fall under this category include the direct 
electrospray probe (DEP) as shown in Figure 1.1(A).1 DEP uses a metal ring or a metal coil that 
contains either an optical fiber or solid phase microextraction (SPME) fiber acting as a probe to 
which the liquid sample is applied; the probe subsequently undergoes ESI.5 The probe prevents 
unnecessary clogging and use of syringe pumps when compared to the use of a capillary  with 
ESI.5 Direct desorption and ionization techniques are characterised by their use of an ambient 
ionization source to generate charged reactive species or metastable atoms which strike the surface 
of the sample leading to the desorption and ionization of the analyte.1 DESI as shown in Figure 
1.1(B) falls under this category. In DESI, a fast stream of solvent droplets charged by ESI strikes 
the surface of the sample at an angle to desorb and ionize analytes from the surface of the sample. 
The ionized analytes are then funneled into the mass spectrometer for analysis. In a two step 
ionization process desorption occurs first followed by ionization. The analyte is desorbed from a 
sample and then interacts with charged reactive species or metastable atoms generated from an 
ambient ionization source to form ions.1 Direct analysis in real time (DART) is a two step 
ionization technique where excited gas atoms, usually helium, are used to ionize atmospheric 
compounds; which in turn ionizes analytes that were desorbed by evaporation or thermal 






Figure 1.1 A graphical summary of AIMS techniques that fall under the different categories 
proposed in Huang et al.1 (A) DEP, a direct ionization technique. (B) DESI, a direct 
desorption/ionization technique. (C) DART, a two-step ionization technique. 
 
The lack of sample preparation in most AIMS techniques and the lack of chromatography has 
greatly reduced the total analysis time, however this set of techniques has its fair set of challenges 
to address and overcome. Three major challenges that AIMS techniques face are reproducibility, 
sensitivity, and selectivity which a perspective from Kuo et al. further explores.7 One major cause 
of all three challenges is the complexity of the samples under analysis and its matrix effects. Matrix 
effects can alter the sensitivity of a method by suppressing the ionization of analytes which is 
particularly troublesome for ESI.8 Additional matrix effect complications arise when using a 
matrix that has a large amount of variation between different samples such as whole blood.9 
Complex matrices can further reduce selectivity as matrix components may have the same mass 
to charge (m/z) ratio. In addition, heterogeneity within a single sample heavily influences the 
analytes ultimately detected and possibly quantified. The ability to analyze sample heterogeneity 
by AIMS is of great interest as indicated by the vast literature published on MS imaging.10 
However, applications only interested in detection and quantitation of analytes without regard to 
spatial information about heterogeneity within a sample can view this as a source of 
irreproducibility due to possible variances in sampling. As a response to these challenges there is 
an interest to integrate sample preparation into AIMS workflows as it reduces matrix interferents 
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and can concentrate analytes.11 This in turn leads to better sensitivity and selectivity. Sample 
preparation techniques used must be fast and/or allow for high throughput or else the workflow 
would not be a practical alternative to a conventional liquid chromatography coupled to mass 
spectrometry (LC-MS) workflow. 
1.2 Sample Preparation Techniques Used in Ambient Ionization Mass Spectrometry 
 
Coupling sample preparation to AIMS leads to a decrease in matrix effects, as well as increases 
in sensitivity, linearity, and/or reproducibility. Sample preparation can be approached by 
modifying an already existing parameter of an AIMS technique or by introducing a new step before 
the AIMS technique.11–13 Paper spray is an AIMS technique that uses paper as a substrate for 
sample deposition and subsequently the substrate from which ESI is generated. Paper spray is an 
example of an AIMS technique that has an inherent sample preparation component.13 The cellulose 
fibers of paper can interact with matrix components which can alter the matrix effect and analyte 
sensitivity.14 Venter et al. and Javanshad & Venter further explore the different sample preparation 
and processing options available by modifying already existing parameters of AIMS 
techniques.12,13 
Tailoring sample preparation step(s) towards the combination of analyte and matrix provides 
increases in sensitivity, reproducibility, and lower matrix effects required for an AIMS workflow 
that is fit for purpose. Sample preparation steps commonly used in LC-MS workflows have been 
incorporated into AIMS workflows.  Liquid-liquid extraction (LLE), solid phase extraction (SPE), 
protein precipitation (PPT) and quick, easy, cheap, effective, rugged, and safe (QuEChERS) are 
conventional sample preparation steps incorporated into AIMS workflows. For example, LLE with 
low temperature partitioning was used by Paula et al. to quantify benzodiazepines from 
beverages.15 Another example is progesterone extracted from lake water by SPE and subsequently 
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quantitated by DART-MS.16 These conventional sample preparation steps can fall into the pitfalls 
of being time consuming or hard to facilitate in a high throughput fashion. Both pitfalls can lead 
to developing a method that can not taken advantage of quick analysis times that AIMS techniques 
with little to no sample preparation provide nor can provide the sensitivity or selectivity that a 
conventional LC-MS method can provide. In addition, the use of several pieces of equipment and 
reagents for a sample preparation step in an AIMS workflow can lead to difficulty when attempting 
to implement AIMS outside of a laboratory. To mitigate these drawbacks sample preparation 
techniques used in AIMS workflows should be relatively quick and/or allow for high throughput 
sample preparation as well as use minimal equipment if attempting to implement an AIMS 
workflow outside of the lab. 
1.3 Solid-Phase Microextraction (SPME) 
  
SPME was introduced by Pawliszyn and can facilitate solventless sampling, sample 
preparation, as well as preconcentration in one step.17  SPME is a micro-extraction technique 
where a small amount of extraction phase generally immobilized onto a solid support is exposed 
to a sample at set experimental conditions for extraction.2 Analytes recovered by said extraction 
phase are ultimately desorbed for further chemical separation and detection or directly to 
detection.18 Optimization of experimental conditions for successful implementation of SPME 
includes but is not limited to geometry of SPME devices, mode of extraction, and coating 
chemistry.19 Detailed reviews on fundamentals and experimental conditions to consider when 
optimizing SPME protocols have been reviewed elsewhere.2,19,20 Using a small volume of the 
extraction phase relative to the sample leads to only the free fraction of the analyte being extracted 
by SPME.2 This non-exhaustive nature of SPME allows for monitoring chemical changes in a 
system with minimal disturbance and measure signals proportional to an analyte’s free 
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concentration.21 However, the non-exhaustive nature of SPME also requires careful consideration 
of which calibration method is used for quantification.3  
Certain calibration methods are better suited for certain regimes on the extraction time profile 
(ETP).22 The three regimes on an ETP are the linear regime, the kinetic regime, and the near 
equilibrium regime as illustrated by Figure 1.2.22 Figure 1.2 is a typical ETP where t50 is the time 
at which 50% of the amount of analyte extracted at equilibrium is extracted. At t95 the amount of 
analyte extracted is 95% of the amount of analyte extracted at equilibrium. The traditional 
calibration methods: external standard calibration, standard addition calibration, and internal 
standard calibration can be applied in all three regimes. Other calibration methods include 
equilibration based calibration which is commonly used for on-site analysis where internal 
standard and standard addition calibration methods are not suitable.21 In cases where equilibration 
of analytes is not practically feasible then kinetic calibration methods can be employed.22 
 
 




1.4 Solid-Phase Microextraction Coupled Directly to Mass Spectrometry 
 
The use of SPME as a sample preparation step to enhance AIMS techniques has been proposed 
before the term AIMS was coined.18 As early as 1999 Kuo & Shiea used an SPME fiber for DEP.5 
SPME allows for fast extractions, particularly when the extraction time falls in the linear 
calibration regime, and uses very little to no solvent. This has made SPME the most commonly 
integrated sample preparation technique for AIMS workflows as reported by Kuo et al.7 The 
benefits of integrating SPME would combat the previously stated challenges of AIMS by reducing 
matrix effects caused by co-extraction and/or co-ionization of unwanted matrix components and 
improving limits of detection (LOD) by concentrating the analytes onto the SPME device. The 
above advantages come without compromising the speed, high throughput capabilities, and ability 
to apply the workflow to an environment outside of the laboratory. AIMS workflows also takes 
better advantage of the enrichment factor provided by SPME when compared to LC-MS 
workflows. This is due to the dilution found in SPME-LC-MS obtained by the desorption of SPME 
devices in relatively large volumes of desorption solution.23  
To date, SPME has been integrated with several AIMS techniques including DART, DESI, 
coated blade spray (CBS) and microfluidic open interface (MOI).18 SPME is incorporated in 
DART workflows through the use of coated thin film meshes that extract analytes which are 
subsequently thermally desorbed during DART.24 In DESI workflows, SPME can be integrated 
using coated substrates that have extracted analytes. A stream of charged solvent droplets desorb 
and ionize analytes off the substrate and into the mass spectrometer.25 MOI uses a flow isolated 
desorption chamber open to the ambient environment to contain desorption solution to desorb 
analytes from an SPME device.26 MOI transports analytes desorbed from the desorption chamber 
to the ionization source given that the ionization source provides constant suction.26 MOI has been 
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coupled with SPME fibers to desorb and subsequently transport analytes into the ionization source. 
Figure 1.3 is a schematic of MOI.26 In CBS a sword shaped stainless steel sheet coated with a 
polymeric coating is used to extract a sample and subsequently used as the substrate for which ESI 
occurs.27 Figure 1.4 is a workflow of CBS.28  SPME can also be implemented in a high-throughput 
fashion as shown by Tascon et at. 2018.29 This highlights the ability to develop high throughput 
SPME-MS workflows that can be used for on-site analysis. 
 
Figure 1.3 MOI schematic (Tascon et al., 2018)26 
 
Figure 1.4 CBS workflow (Gómez-Ríos et al., 2018)28 
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1.5 Probe Electrospray Ionization 
 
Probe electrospray ionization (PESI) was introduced by Hiraoka et al. in 2007.30 This 
technique utilizes a small untreated metal probe with a diameter in the micrometer range and a 
sharp tip with a diameter usually in the low micrometer or sub micrometer range.30 The probe 
moves from position A in Figure 1.5(A) where the tip of the probe picks a small amount of sample 
upwards to position B where the probe is usually 3mm above the sampling cone of the mass 
spectrometer, high voltage is then applied to induce ESI as illustrated in Figure 1.5(A).30 For a 
liquid sample picked by the probe it is retained as a thin liquid film by surface tension between the 
sample and the probe when moving from position A to position B.30 The application of high 
voltage causes the formation of a Taylor cone from the thin liquid film at the probe’s tip.   
The picking and spraying of sample during PESI are unique amongst AIMS techniques and 
has led to the study of its physical parameters to gain a better understanding of the technique’s 
fundamentals. The size of the droplets formed by ESI is dependent on the size of the probe’s tip in 
the same manner as a capillary’s size is for ESI emiters.31 The liquid flow rate to form the droplet 
is dependent on the amount of liquid loaded onto the needle and the voltage applied.31 The use of 
a needle rather than a capillary prevents clogging issues which is also seen in DEP.5,30 The initial 
droplets formed by PESI are extremely small which in turn can decrease ion suppression which is 
also seen in nano-ESI.31 Yoshimura et al. demonstrated that PESI picks up sample volumes in the 
low pL range using a stainless steel acupuncture needle with a diameter of 140µm and a tip 
diameter of 700nm. Yoshimura also demonstrated that the volume of sample picked during PESI 




Figure 1.5 (A) Schematic of a PESI experiment (B) resulting TIC (Hiraoka et al.) 30 
 
 Most PESI experiments utilizes a continuous pick and spray process where the needle 
continuously picks the sample and sprays it multiple times. The resulting total ion chromatograms 
are characteristic of Figure 1.5(B).30 The continuous pick and spray process allows PESI to 
monitor chemical reactions in real time and real time analysis of living animals.32,33 PESI can also 
be run such that the sample is only picked and sprayed once, this is referred to as single-shot 
PESI.34  
The original configuration of PESI as highlighted in Figure 1.5(A) has two practical 
shortcomings; the first is that the sample cannot be dry and the second is how close the probe is to 
the inlet of the mass spectrometer. A variant of PESI, sheath flow PESI (SF-PESI) where the PESI 
probe protrudes out of a gel loading tip was designed to allow wetting of dry samples and cleaning 
of the needle. A syringe pump supplies solvent into the gel loading tip allowing for the probe to 
be wetted before picking a sample. Figure 1.6 shows a schematic of SF-PESI.35 The biggest 
samples used in PESI experiments published to date are mice.36 If samples are moderately sized 
then the normal PESI setup is unfeasible.37 Literature shows attempts to remedy this by having the 




spectrometer.37 The introduction of a 200 mm ion sampling tube required the use of an additional 
vacuum pump to obtain ion transfer efficiencies similar to that of the original PESI setup.37  Other 
methods to work around the issue of sampling having to be done so close to the mass spectrometer 
inlet includes dipping PESI (dPESI). In dPESI the probe picks the sample offline and is allowed 
time for the sample picked onto the probe to dry. Afterwards the PESI procedure is done with its 
normal setup as shown in Figure 1.5(A) except at position A the probe picks on a wetting solvent 
instead of the sample. 
 
Figure 1.6 Sheath flow probe electrospray ionization (Mandal et al. 2013)38 
 
With all its various formats, PESI has been used for various applications from the detection of 
compounds in food stuff, living mice, and whole blood. Quantification of analytes is 
underrepresented in PESI literature. A large portion of this can be attributed to matrix effects as 
the lack of sample preparation in most PESI applications leads to less sensitive measurements. 
Usui and collaborators demonstrated the quantitative capabilities of PESI by performing sample 
preparation before PESI analysis.39–42 The most common sample preparation method used was a 
dilution with a solvent containing internal standards (IS) before a 10µL aliquot was used for PESI-
MS. This dilution method is an extremely fast and simple sample preparation method allowing for 
12 
 
near real time analysis. However, analytes are diluted leading to a higher limit of quantitation 
(LOQ) compared to other sample preparation methods. This is shown by the LOQ of 
acetaminophen from blood serum and glyphosate from human serum being 1.56µg mL-1 for both 
cases.40 Usui and collaborators have also quantified MT-45 from tissue via standard addition. In 
this case QuEChERS was applied for sample preparation.39 Although an LOQ was not stated for 
this application depending on the tissue type used the lowest calibration point was either 20 ng 
mL-1 or 80 ng mL-1.39 The PESI-MS method using QuEChERS had a far lower LOQ compared to 
the other quantitative PESI workflows due to sample cleanup. Hisatsune et al. reported 
quantification of cyanide in 2µL of whole blood using a 10 min derivatization step before being 
quantitated by PESI-MS/MS. the reported was LOD of 42 ng mL-1.43 Further sensitivity increases 
for PESI can arise from pre-concentrating analytes from samples before MS analysis. 
1.6 Solid-Phase Microextraction Probe Electrospray Ionization 
 
SPME has been used as a sample preparation technique for PESI by Bernardo et al. and da 
Silva et al.44,45 In these implementations of SPME-PESI-MS the probe is kept close to the mass 
spectrometer inlet and desorption solvent is applied to the probe by a system such as a syringe 
instead of the probe picking the desorption solvent. It should also be noted that the probes used 
were 500 µm in diameter for these studies. The used probes are significantly bigger than probes 
typically used for PESI which are 120 µm in diameter. Bernardo et al. was able to obtain LOQs of 
2.05 ng mL-1 and 8.78 ng mL-1 for cocaine in saliva and urine, respectively.44 In the case of da 





Figure 1.7 (A) PESI probe set up from Bernardo et al.44 (B) PESI probes set up from da Silva et 
al.45  
 
Further coupling of SPME as a sample preparation with commercial PESI probes produced by 
Shimadzu is of interest. Coating commercial PESI probes (120 µm in diameter, 5 mm in length, 
and 700 nm tip diameter) which were used in quantitative examples from section 1.5 can yield 
interesting applications in areas such as prenatal screening and post-mortem analysis. This is due 
to the possibility of leveraging the preconcentration and extraction of SPME with the small 
dimension of PESI to analyze samples where minimal amounts are available for analysis directly 
with an MS. Ultimately the goal of this body of work is to lay the foundation for the above 
mentioned possible applications. This was done by studying the basic characteristics of SPME-
PESI coupled to tandem mass spectrometry (SPME-PESI-MS/MS), leveraging the small 
dimensions for plasma protein binding, and finally explore challenging compounds. In chapter 1, 
a study into evaluating the coating of commercial PESI probes, the characteristics of SPME-PESI-
MS/MS and finally using SPME-PESI-MS/MS to quantify drugs of abuse from small volumes of 
plasma was conducted. In chapter 2, the small size of the coated PESI probes was leveraged to 
perform a proof of concept regarding determination of plasma protein binding of diazepam from 
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human plasma. Finally, in chapter 3, a basic exploration of screening aminoglycosides with SPME-






















Screening and quantitating analytes at low cost and high speed has gained much attention 
in mass spectrometry. To meet this demand there is a focus on AIMS techniques where 
chromatography is not utilized before the introduction of sample to the mass spectrometer with 
little to no sample preparation. The lack of chromatography leads to an increase in throughput and 
a decrease in overall analysis time. The development of DESI and DART popularized AIMS by 
several aspects including throughput, speed, and reduced cost.4,46 The number of AIMS techniques 
have exploded since the introduction of DESI and DART with at least 70 different techniques.11 
Other prominent techniques that have arisen include paper spray, dielectric barrier discharge, and 
PESI.30,47,48 
PESI was initially reported by Hiraoka et al. in 2007 which consists of lowering a small 
conical metal probe moving downwards to be dipped into a sample followed by a rapid upwards 
movement to a position usually 3 mm higher than the mass spectrometer inlet for the application 
of high voltage and the process is repeated multiple times.30 PESI allows for the consumption of 
small amounts of sample as the amount of sample adhered on to the probe is in the low pL per pick 
and spray cycle.49 The use of a probe avoids clogging issues found when using capillaries and the 
small tip of the probe leads to smaller initial droplets being formed by conventional ESI 
capillaries.31 PESI has also been shown to be more tolerate to salts when compared to conventional 
ESI capillaries.31 PESI has branched out from its original configuration to alternative 
configurations such as sheath flow PESI and non-proximate PESI.35,37 Literature has shown PESI 
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to have a wide variety of applications including rapid drug determination, metabolic profiling of 
live mice, and chemical profiling of tulips.33,42,50  
Despite the large amount of interest in AIMS there is not a relatively large uptake for using 
AIMS in applications. A perspective by Kuo et al. 2020 highlights several challenges that AIMS 
must overcome before more mainstream usage is adopted.7 The challenges include better 
reproducibility, quantification, and sensitivity. Integration of sample preparation increases 
sensitivity and quantification by decreasing matrix effects and/or increasing analyte 
concentration.7 In selecting an appropriate sample preparation technique, it should be fast and/or 
allows for high throughput or else an AIMS workflow would lose much of its benefits when 
compared to a chromatographic counterpart. Most literature reporting on PESI focuses on 
qualitative studies. It is important to note that most studies reporting the use of PESI quantitatively 
has some level of sample preparation namely dilution with organic solvent or QueCHERs.39–43 
One sample preparation method that is fast, allows for high throughput, and easily 
integrates into an AIMS workflow is SPME. Kuo et al. 2020 highlighted SPME as the most 
popularized method of sample pre-treatment for AIMS.7 SPME was initially developed for 
analysis of organics in water.51 Since then SPME has matured as a sample preparation technique 
to many fields from environmental to bioanalytical.52–54 The integration of SPME to commonly 
used AIMS workflows such as DESI, DART, and nano-ESI.55–57 Further introductory information 
of SPME based AIMS techniques can be found in a review article by Gómez-Ríos & Mirabelli.18 
 SPME was coupled with PESI by Bernardo et al. to extract drugs of abuse from oral fluids 
and urine.44 In addition, da Silva LC et al. used SPME-PESI to extract phorbol esters from 
Jatropha curcas leaves.45 These conjunctions of coated probes are large enough that the 
application of desorption solvent is feasible using a pipette or syringe. In this chapter the 
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development and application of SPME-PESI-MS/MS using commercially available PESI probes 
coated with polymeric material and the DPiMS-8060 interface was the focus. The probe 
dimensions made the application of desorption solvent not practical by syringe or pipette, therefore 
the repetitive pick and spray cycle method was used. The development of the probe was tested 
using drugs of abuse in phosphate buffered saline (PBS) and then for detecting the drugs of abuse 
in small volumes of plasma was developed.  
2.2 Experimental 
 
2.2.1 Chemicals and materials 
 
LC-MS grade acetonitrile (ACN), isopropanol (IPA), methanol (MeOH), and water (H2O) 
were purchased directly from Fisher Scientific (Bartlesville, OK, USA). FA, sodium chloride, 
potassium chloride, potassium phosphate monobasic, sodium phosphate dibasic, hydrochloric 
acid, HPLC grade MeOH were purchased from Sigma Aldrich (Oakville, ON, Canada). The 
following chemical were purchased from Sigma Aldrich (Oakville, ON, Canada) specifically for 
the synthesis of 1.3µm HLB particles; divinylbenzene, N-vinylpyrrolidone, and 2,2-
Azobis(isobutyronitrile). The analytical standards and their deuterated analogues were purchased 
from Cerilliant Corporation (Round Rock, TX, USA): buprenorphine, codeine, diazepam, 
fentanyl, lorazepam, nordiazepam, oxazepam, propranolol, buprenorphine-d4, codeine-d3, 
diazepam-d5, fentanyl-d5, lorazepam-d4, nordiazepam-d5, and propranolol-d7. The deuterated 
analogue of the standards was used for IS correction when applicable. The exception was for 
oxazepam where nordiazepam-d5 was used as the internal standard when applicable. Frozen, 
pooled gender, non- filtered human plasma with K2EDTA as the anticoagulating agent was 
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purchased from Bioreclamation IVT (Westbury, NY, USA). PESI probes and sample plates were 
kindly donated by Shimadzu Corporation (Kyoto, Japan).  
 Methanolic working standards were prepared from the master standards of analytes listed 
in Table 2.1 with concentrations such that only a maximum of 1% organic working standard was 
spiked into samples of PBS or plasma. This was to prevent alterations to the matrix that can 
measurably affect either the equilibrium constant between the coated probe and the sample. 
 The HLB synthesis procedure and PBS preparation procedure from the supplemental 
information of Vasiljevic et al. was followed.58,59 An in-house built stage equipped with a motor 
(MTS50/M-Z8E, 50 mm) from ThorLabs Inc. (Newton, MA, USA) was used for dip coating the 
PESI probes.  
2.2.2 LC-MS/MS Instrumentation and Method 
 
LC-MS/MS experiments were conducted on a Shimadzu LCMS 8060 (Kyoto, Japan) triple 
quadrupole mass spectrometer with Shimadzu LC-30AD liquid chromatography system (Kyoto, 
Japan). Detailed information on the selected reaction monitoring transitions used to quantify 
analytes for the LC-MS/MS experiments can be found in Table 2.1. Further experimental 
conditions about the LC-MS/MS method can be found in Table 2.2 and Table 2.3. The autosampler 
was thermostated to 4˚C and used for injection of 3µL or 6µL of PBS or plasma extracted samples, 
respectively. A Phenomenex Kinetex PFP column (2.1 x 100 mm x 1.7 µm particle size) was 
purchased directly from Phenomenex (Torrance, CA, USA) was used for separation. The column 
oven was thermostated to 35˚C and the flow rate used was 300 µL/min. Mobile phase A was water 
while mobile phase B was  MeOH/ACN (v/v, 7/3) and both mobile phases contained 0.1% formic 
acid. The gradient was run at 10% B for 1.0 min, linearly ramped to 100% B until 7.0 min, and 
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held at 100% B until 9.0 min. The column returned to 10% B at 9.2 min and allowed to re-
equilibrate until 11.0 min. 
Table 2.1 Multiple Reaction Monitoring Parameters for Drugs of Abuse 











1 Buprenorphine Buprenorphine-d4 4.98a 468.3 55.1 -11 -50 -21 
1 Buprenorphine Buprenorphine-d4 4.98a 468.3 396.3 -11 -39 -30 
2 Buprenorphine-d4   472.3 59.2 -11 -52 -22 
3 Codeine Codeine-d3 1.39a 300.2 165.2 -11 -42 -11 
3 Codeine Codeine-d3 1.39 a 300.2 215.2 -11 -24 -15 




-11 -26 -15 
5 Diazepam Diazepam-d5 2.82 a 285.0 193.1 -11 -30 -13 
5 Diazepam Diazepam-d5 2.82 a 285.0 154.1 -11 -27 -16 
6 Diazepam-d5   290.3 198.1 -11 -32 -21 
7 Fentanyl Fentanyl-d5 4.05 a 337.2 188.3 -10 -24 -13 
7 Fentanyl Fentanyl-d5 4.05 a 337.2 105.1 -10 -38 -20 
8 Fentanyl-d5   342.3 188.2 -13 -24 -13 
9 Lorazepam Lorazepam-d4 2.39 a 321.0 275.1 -12 -21 -20 
9 Lorazepam Lorazepam-d4 2.39 a 321.0 229.1 -12 -29 -24 
10 Lorazepam-d4   325.2 279.0 -10 -24 -19 
11 Nordiazepam Nordiazepam-d5 2.79 a 271.0 140.1 -10 -26 -25 
11 Nordiazepam Nordiazepam-d5 2.79 a 271.0 165.1 -10 -27 -17 
12 Nordiazepam-d5   276.2 213.2 -11 -27 -15- 
13 Oxazepam Nordiazepam-d5 2.24 a 286.9 241.1 -11 -24 -16 
13 Oxazepam Nordiazepam-d5 2.24 a 286.9 269.1 -14 -16 -19 
14 Propranolol Propranolol-d7 3.48 a 260.4 116.2 -10 -17 -22 
14 Propranolol Propranolol-d7 3.48 a 260.4 183.1 -10 -18 -12 
15 Propranolol-d7   267.2 116.2 -10 -19 -12 
a LogP values retrieved from Drug bank, accessed in April 2020 
Note that product ions bolded are the quantitative ions. Pause time and dwell time for all compounds were both 1 msec 
 
Table 2.2 MS conditions for LC-MS/MS 
MS parameters on the LCMS-8060 
Ionization Mode ESI  
Interface voltage 4.0 kV (positive)  
Interface temperature 300 °C 
Desolvation line temperature 250 °C 
Heating block temperature 400 °C 
Nebulizing gas flow 3.0 L/min 
Drying gas flow 10.0 L/min 
Heating gas flow 10.0 L/min 
Collision gas and pressure Argon, 270 kPa 




Table 2.3 LC Conditions 
 Optimized LC conditions 
Column 
Phenomenex Kinetex PFP Column 
2.1 x 100 mm, 1.7 µm particle size, 100Å Torrance, CA, USA 
Mobile phase 
A: water with 0.1% formic acid 
B: methanol/acetonitrile (v/v 7/3) with 0.1% formic acid 










3 µL for PBS extracts 
























2.2.3 SPME-PESI-MS/MS Instrumentation and Method  
 
SPME-PESI-MS/MS experiments were conducted using a Shimadzu DPiMS-8060 
interface (Kyoto, Japan) and a Shimadzu LCMS 8060 (Kyoto, Japan) triple quadrupole mass 
spectrometer. Extensive instrumental details and optimized DPiMS-8060 interface and MS/MS 
parameters are provided in Tables 2.1, 2.4, and 2.5. The outage time in the sample position was 
50ms, and the outage time in the ionization position was 200ms. An interface voltage of 2.3kV 
was applied when the probe was at the ionization position. The total acquisition time per sample 
was set to 0.56 min. 
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Table 2.4 DPiMS-8060 Parameters for PESI-MS/MS 
   MS parameters on the LCMS-8060 
Extraction Mode   Top Position -44.00 mm  
   Bottom Position -46.00 mm  
   Count 1 
   Probe Speed 250.00 mm/s 
   Probe Acceleration 1.00 G 
Analysis Mode   Ionization Position -37.00 mm 
   Outage time (Ionization Position) 200 ms 
   Sample Position -46.00 mm 
   Outage time (Sample Position) 50 ms 
   Probe Speed 250 mm/s 
   Probe Acceleration 0.63 G 
 
Table 2.5 Optimized MS conditions for SPME-PESI-MS/MS 
MS parameters on the LCMS 8060 
Ionization Mode ESI  
Interface voltage 2.3 kV (positive)  
Desolvation line temperature 250 °C 
Heating block temperature 30 °C 
Collision gas and pressure Argon, 270 kPa 
Pause Time  1 ms 
Dwell Time 1 ms 
 
2.2.4 Preparation of Coated PESI probes 
 
A 7% (weight/volume) solution of polyacrylonitrile (PAN) in dimethylformamide (DMF) 
was prepared and will be referred to as the coating binder. A slurry with a composition of 9.2% 
1.3µm HLB particles, 87.9% of coating binder, and 2.8% glycerol by weight was then prepared. 
PESI probes were etched by sonication in dilute HCl (7.4%) for 15 min. The probes were then 
sonicated in water for 20 min followed by sonication in LC grade MeOH for another 20 min. The 
etched probes were then dried in a convection oven at 125˚C and were coated the same day as the 
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etching. The etched PESI probes were dip-coated with the HLB-PAN slurry using an in-house 
built stage. The tips of the probes were coated with a length of 2 mm and dried in a convection 
oven at 90˚C. This coating process was repeated until a coating thickness of 6.5 µm was achieved. 
Prior to using the coated PSEI probes for extractions, the probes were cleaned with a 
MeOH/ACN/IPA (v/v/v 2/1/1) mixture for 15 min, followed by conditioning with MeOH/H2O 
(v/v 1/1) for 15 min. 
2.2.5 Assessment of Coated PESI Probes by LC-MS/MS using PBS 
 
All experiments performed in this section used 300µL aliquots of PBS spiked with 10 ng 
mL-1 of standards as samples. In between extraction and desorption, the probes were rinsed with 
H2O for 3s and air dried. All experiments also used 50µL of MeOH/ACN (v/v 4/1) as the 
desorption solution for subsequent LC-MS/MS analysis. All extractions and desorptions were 
static and performed at room temperature. 
ETP of the coated PESI probes in PBS was constructed using the following extraction times 
in triplicate: 10, 30, 60, 90, and 120 min. Extraction was followed by a 3s rinse in H2O and a 30 
min desorption. 
Desorption time profile (DTP) of the coated PESI probes in PBS was constructed via 
extraction using the optimal extraction time. Afterwards the following time points for desorption 
were tested in triplicate: 10, 30, 45, 60, and 75 min. Subsequently a second desorption was 
conducted immediately after the first with fresh desorption solvent for 75 min. The second 
desorption was used to assess carryover of the analyte. 
  Intra-probes reproducibility was tested by five cycles of extraction and desorption of 
coated PESI probes using optimized extraction and desorption conditions. Inter-probe 
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reproducibility was determined by grouping the probes from the intra-probe reproducibility test by 
their extraction and desorption cycle. 
2.2.6 SPME-PESI-MS/MS Assessments in PBS 
 
 In this section 90 min static extractions at room temperature were performed using 300 µL 
PBS spiked with 10 ng mL-1 standards as samples. The extraction was followed by a rinse with 
H2O for 3s and air drying the coated PESI probes. 
The desorption solution for SPME-PESI-MS/MS was optimized by placing the dry 
extracted probe into the DPiMS- 8060 interface and 10 µL of desorption solution was applied to 
the sample plate. Finally, an SPME-PESI-MS/MS run was conducted. The desorption solutions 
tested varied in ratios of water to organic solvent with 0.1% formic acid. The organic solvents used 
were ACN, IPA, and MeOH.  
 To test depletion of the coated PESI probes by SPME-PESI-MS/MS three distinct 
scenarios were used after extraction, rinsing, and drying the coated PESI probes as follows below:  
1) The coated PESI probes underwent a 30 min static desorption into 50 µL MeOH/ACN (v/v 4/1) 
for LC-MS/MS analysis.  
2) The coated PESI probes were used for SPME-PESI-MS/MS using 10 µL of the optimized 
desorption solvent. Following this the coated PESI probes underwent a 30 min static desorption 
into 50 µL MeOH/ACN (v/v 4/1) for LC-MS/MS analysis.  
3) The coated PESI probes were used for SPME-PESI-MS/MS two consecutive times using the 
optimal desorption solvent. Following this the coated PESI probes underwent a 30 min static 
desorption into 50 µL MeOH/ACN (v/v 4/1) for LC-MS/MS analysis. 
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2.2.7 Extraction from Small Volumes of Plasma 
 
All plasma samples when spiked with analytes were incubated in a 4˚C refrigerator 
overnight to allow for adequate binding with plasma.  
Extraction time profile of the coated PESI probes was conducted using aliquots of 30µL 
plasma spiked with 10 ng mL-1 of standards were statically extracted for the following time points: 
10, 30, 45, 60, 75, and 90 min. Extraction was followed by a 3s rinse and a 30 min static desorption 
in 50µL MeOH/ACN (v/v 4/1) for LC-MS/MS analysis.  
 SPME-PESI-MS/MS was used to construct calibration curves by extracting 30 µL of 
plasma with 10 ng mL-1 of internal standards and the following concentrations of standards: 1, 5, 
10, 25, 50, 75, 100 ng mL-1. Precision and accuracy were determined by three different QC levels 
which were plasma spiked with the following concentrations of standards: 3, 30, and 90 ng mL-1. 
Five replicates were used per calibration level and QC level. 
2.3. Results and Discussion 
 
2.3.1 Extraction Time Profiles and Coated PESI Probe Reproducibility in PBS 
 
The first major objective was to investigate the reproducibility of coating the PESI probes. 
Before conducting intra- and inter- probe reproducibility ETP and DTP were performed to ensure 
adequate signal was obtained and carryover of analytes are minimized. The initial ETP attempted 
using agitation, however the reproducibility was poor therefore static extractions and desorptions 
were used. This can be due to the lack of control over the coated PESI probe contacting the sample 
or desorption solvent.58 ETPs were determined by the static extraction from PBS spiked with 10 
ng mL-1 of standards using time points ranging from 10 – 120 min. ETPs can be found in Figure 
2.1 and based on these results 90 min was selected as the optimized extraction time despite the 
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compounds not reaching equilibrium. A 90 min static extraction was used as the optimal time as 
it allowed for the completion of five consecutive extraction and desorption cycles for the inter and 
intra probe reproducibility in a practical time frame while attaining high sensitivity. The DTP was 
determined by the static extraction of spiked PBS for 90 min followed by the desorption for the 
following time points: 10, 30, 45, 60, and 75 min. A second static desorption step was carried out 
to assess the carryover of analytes. Results of the desorption time profile experiment show that all 
analytes are desorbed quantitatively at 10 min. However, the carryover test shows that all 
compounds carryover percentages of 3.5% or less except propranolol and buprenorphine which 
had relatively high carryover percentages of 5.0 and 5.3% respectively. Therefore, a desorption 
time of 30 min was considered as the best desorption time, where all compounds had carryover at 




Figure 2.1 Extraction time profile of drugs of abuse in PBS (A) buprenorphine (B) codeine (C) 
diazepam (D) fentanyl (E) lorazepam (F) nordiazepam (G) oxazepam (H) propranolol 
 
Intra-probe reproducibility was conducted by five consecutive extraction and desorption 
cycles using a 90 min extraction time and 30 min desorption time. The intra-probe reproducibility 
was used to observe the stability of the coated probes and the reusability of the probes. Intra-probe 
reproducibility was excellent as shown in Table 2.6. Good intra-probe reproducibility was 
demonstrated by 34 instances where relative standard deviations (RSDs) were 10% or less, 4 
instances where RSDs were between 10 – 15%, and two instances where RSDs were between 15 
– 20%. Inter-probe reproducibility was determined by grouping the results of the intra-probe 




















reproducibility show good reproducibility of the etching and coating process as shown in Table 
2.7. Good inter-probe reproducibility was demonstrated by 26 instances where RSDs were 10% or 
less, 11 instances where RSDs were between 10 – 15%, 6 instances where RSDs were between 15 
– 20% and one instance where the RSD was 21%. When compared to the SPME mini tips, a similar 
device the inter- and intra-probe reproducibility were equal or lower than said literature values.58 
Vasiljevic et al. assessed intra-tip reproducibility for SPME mini tips by evaluating the RSDs of 
five extraction and desorption cycles using 200 ng mL-1 of diazepam, nordiazepam, oxazepam, 
and lorazepam58. Only 7 out of the 20 RSDs for the said compounds were 10% or less for the 
SPME-mini tips.58 In comparison for the coated PESI probes 18 out of the 20 RSDs for the said 
compounds were 10% or less. For the inter-tip reproducibility test for the SPME mini tips the 
lowest RSD between diazepam, lorazepam, nordiazepam, or oxazepam was 18% while the highest 
RSD for the coated PESI probes for the said compounds was 16%.58 
Table 2.6 Intra-probe reproducibility of coated PESI probes  
 RSD (%) n = 5 
Probe 
Number Buprenorphine Codeine Diazepam Fentanyl Lorazepam Nordiazepam Oxazepam Propranolol 
1 16 10 6 8 4 5 4 6 
2 12 3 7 9 5 6 6 8 
3 7 10 9 10 7 9 8 9 
4 6 15 5 4 10 8 10 7 
5 9 20 5 4 11 6 11 6 
 
Table 2.7 Inter-probe reproducibility of coated PESI probes 
 
RSD (%) n = 5 
Extraction 
Cycle Buprenorphine Codeine Diazepam Fentanyl Lorazepam Nordiazepam Oxazepam Propranolol 
1 7 14 7 6 7 7 6 6 
2 5 20 8 7 14 10 13 8 
3 15 21 14 15 15 14 16 15 
4 11 7 9 11 6 9 7 9 
5 7 8 3 4 4 3 4 5 
28 
 
2.3.2 Basic SPME-PESI-MS/MS Studies 
 
With the extraction conditions optimized for SPME-PESI-MS/MS via the ETP done in the 
prior section, the desorption solvent was optimized for SPME-PESI-MS/MS. The following 
desorption solutions were tested: ACN/H2O (v/v 9/1), ACN/H2O (v/v 7/3), ACN/H2O (v/v 1/1), 
IPA/H2O (v/v 9/1), IPA/H2O (v/v 7/3), IPA/H2O (v/v 3/2), IPA/H2O (v/v 1/1), IPA/H2O (v/v 2/3), 
MeOH/H2O (v/v 9/1), MeOH/H2O (v/v 7/3), and MeOH/H2O (v/v 1/1). All solvents listed above 
had 0.1%FA added as a modifier. Figure 2.2 shows the results of these experiments using 
normalized area counts. Area counts were normalized by dividing area counts for all desorption 
solvents for a particular compound by the desorption solvent that gave the highest average area 
count. Data for ACN/H2O (v/v 9/1), ACN/H2O (v/v 7/3), ACN/H2O (v/v 1/1), and IPA: H2O (v/v 
9/1) were not included in Figure 2.2. These data points were excluded due to the inconsistency in 
the generation of spray events when using these desorption solvents. The desorption solvent 
IPA/H2O (v/v 1/1) + 0.1% FA was chosen as the optimal desorption solvent as it gave the highest 
area counts for all eight compounds. Unlike other SPME based ambient mass spectrometry 
technologies such as CBS the organic solvent used was IPA compared to MeOH.54 The amount of 
desorption solvent applied onto the coated PESI probe by the repetitive pick and spray method is 
heavily influenced by the surface tension and viscosity of the desorption solvent. An investigation 
by Yoshimura et al. shows a positive correlation between the increase in surface tension and 
viscosity with an increase of the amount of sample picked and retained onto the surface of a PESI 
probe.49 The desorption solvent must also be able to sufficiently wet the coating of the SPME PESI 




Figure 2.2 Desorption solution optimization for SPME-PESI-MS/MS. 
Figure 2.3 illustrates the difference between the electrospray patterns of SPME-PESI-
MS/MS and PESI-MS/MS. The signal height is roughly constant for uncoated PESI probes (Figure 
2.3(C)). The signal height for the coated PESI probes when sampling analytes spiked into the 
sample plate as if it were uncoated PESI probes show an increase in signal height until the 9s mark 
afterwards the signal height is constant (Figure 2.3(B)). The signal height decreases throughout 
the SPME-PESI-MS/MS run when running extracting spiked PBS (Figure 2.3(A)). The hypothesis 
for this decrease in Figure 2.3(A) was that significant depletion of the analytes extracted on the 

























IPA/H2O (2/3 v/v) + 0.1%FA IPA/H2O (1/1 v/v) + 0.1% FA IPA/H2O (3/2 v/v) + 0.1%FA
IPA/H2O (7/3 v/v) + 0.1%FA MeOH/H2O (1/1 v/v) + 0.1%FA MeOH/H2O (7/3 v/v) + 0.1%FA




Figure 2.3 Peak heights from the selected ion monitoring of fentanyl (m/z 337.2) (A) A coated 
PESI probe statically extracted 300µL of PBS spiked with 10 ng mL-1 fentanyl for 90 min, 
followed by a 3s rinse in H2O. Then the coated probe was desorbed using 10µL of IPA/H2O (1/1 
v/v) + 0.1% FA applied to a PESI sample plate by SPME-PESI-MS/MS (B) A coated PESI probe 
was used for PESI-MS/MS of 10µL IPA/H2O (1/1 v/v) + 0.1% FA spiked with 10 ng mL
-1 fentanyl 
applied onto a sample plate. (C) An unmodified PESI probe was used for PESI-MS/MS of 10µL 
IPA/H2O (1/1 v/v) + 0.1% FA spiked with 10 ng mL
-1 fentanyl applied onto a sample plate. Figure 
2.3 was cropped from LabSolutions © Postrun. 
 
This hypothesis of whether extracted coated PESI probes were significantly desorbed by 
SPME-PESI-MS/MS was tested by the extraction of spiked PBS sample followed by either of the 
three scenarios; directly desorbed for LC-MS/MS, used for one SPME-PESI-MS/MS run followed 
by desorption for LC-MS/MS, or used for two consecutive SPME-PESI-MS/MS runs followed by 
desorption for LC-MS/MS. Results from this experiment are shown in Table 2.8 expressed as 
depletion percentages. Depletion percentages are expressed relative to the area counts given by 
coated probes that were directly desorbed for LC-MS/MS without any SPME-MS/MS experiments 
(equation 1). One SPME-PESI-MS/MS run shows at least a 45% desorption of a given compound. 













percentage compared to just one SPME-PESI-MS/MS experiment. The desorption percentages are 
relatively similar. Throughout a single SPME-PESI-MS/MS run it is most likely that the sharp 
decrease in signal height is due to less analytes on the coating as the run progresses. This is also 
shown in Table 2.9 where the decrease in area count in the second consecutive SPME-PESI-
MS/MS run is expressed relative to the area count in the first SPME-PESI-MS/MS run calculated 
by equation 2. All analytes show at least a 77% decrease in area count for the second consecutive 
SPME-PESI-MS/MS run. This also means a single coated PESI probe can not be used for 
screening and confirmation analysis by SPME-PESI-MS/MS followed by LC-MS/MS, 
respectively.  
Table 2.8 Desorption of Analytes from Coated Probes by SPME-PESI-MS/MS Analyzed Using 
LC-MS/MS  
 Percentage Desorption (%) n = 5 
Number of SPME-
PESI-MS/MS runs Buprenorphine Codeine Diazepam Fentanyl Lorazepam Nordiazepam Oxazepam Propranolol 
1 78 68 57 57 61 54 57 46 
2 77 67 65 60 67 62 65 50 
  
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐷𝑒𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 = (1 −








) ∗ 100%     (1) 
 
Table 2.9 Desorption of Analytes from Coated Probes by SPME-PESI-MS/MS Between 
Successive Runs 
  Buprenorphine Codeine Diazepam Fentanyl Lorazepam Nordiazepam Oxazepam Propranolol 
Decrease of Signal 
(%) (n = 5) 89 77 80 81 85 80 81 81 
 
𝐷𝑒𝑐𝑟𝑒𝑎𝑠𝑒 𝑜𝑓 𝑆𝑖𝑔𝑛𝑎𝑙 = (1 −








) ∗ 100%     (2) 
 
The shape of the signal for SPME-PESI-MS/MS illustrated by Figure 2.3(A) is due to a 
single pick and spray not being sufficient for complete desorption of analytes. Xu et al. described 
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the desorption of analytes from the coating to the desorption solvent as partitioning process where 










              (4) 
Based on equation 3 the ratio of analyte desorbed from the coated PESI probe, 𝐸𝑙𝑢. is 
dictated heavily by the desorption solvent volume, Ve, when using coated PESI probes with a 
constant coating volume, Vf. Based on this equation the desorption of nearly all the analytes into 
the desorption solvent for LC-MS/MS analysis occurs due its relatively high volume of desorption 
solvent when compared to the coating volume. Based on the equation only a fraction of analytes 
are desorbed during a single pick and spray for SPME-PESI-MS/MS (equation 4). The amount of 
desorption solvent picked by SPME-PESI-MS/MS is probably in the same range as the amount of 
sample picked by PESI-MS/MS which is in the pL range.49 This explains why each pick and spray 
for a coated PESI probe has observable signals for both its consecutive uses in SPME-PESI-
MS/MS and signal for a subsequent LC-MS/MS run. The decrease in peak area and peak height in 
only a few pick and spray cycles for SPME-PESI-MS/MS can be related to the moles of analytes 
remaining on the coated PESI probe if the desorption volume picked is constant between pick and 
spray cycles as described by equation 4. Each subsequent desorption will have a lower number of 
moles of analyte remaining on the coated PESI probe therefore the concentration of analytes in the 
desorption solvent, 𝐶𝑒 will also decrease.  
2.3.3 Application of SPME-PESI-MS/MS with Plasma 
 
SPME-PESI-MS/MS was then applied to quantitate drugs of abuse in a small volume of 
plasma. The purpose of using plasma was to demonstrate analyte quantitation from a complex 
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matrix where its constituents bind to the analytes and can cause ion suppression even if they are 
extracted in moderate amounts. The ETP of 30µL of spiked plasma was conducted and resulted 
within an optimal time of 60 min as shown in Figure 2.4 due to most compounds reaching 
equilibrium at this time. Afterwards, a calibration curve with seven different calibration levels with 
five replicates per level was constructed. Calibration curves constructed were weighted by a factor 
of 1/x. Table 2.10 contains factors for the line of best fit while Table 2.11 contains the other figures 
of merit. Figure 2.5 contains the calibration curves for the eight drugs of abuse. Intra- and inter-
day precision and accuracy were assessed using three distinct levels with five replicates per levels: 
low, middle, and high (3, 30, 90 ng mL-1). The calibration curves show linearity with R2 values all 
above 0.9800 with six calibration curves showing R2 values above 0.9900. LOQ of the drugs of 
abuse were calculated by determining the lowest calibration point with a signal to noise ratio of 10 
or above. Nordiazepam and fentanyl had a LOQ of 1 ng mL-1. Buprenorphine, codeine, diazepam, 
lorazepam, and propranolol had a LOQ of 5 ng mL-1. Oxazepam had a LOQ of 10 ng mL-1. Intraday 
precisions were under 15% for all compounds for concentrations above their respective LOQs. 
Inter-day precisions were under 15% for all compounds except for the middle level of lorazepam 
and the high level of oxazepam which were 16 and 27% respectively. Accuracies were between 
80 – 120% for all compounds for concentrations above their respective LOQs except for the middle 











Figure 2.4 Extraction time profile of drugs of abuse from small volume plasma samples by LC-MS/MS 
(A) Buprenorphine (B) Codeine (C) Diazepam (D) Fentanyl (E) Lorazepam (F) Nordiazepam (G) 













Extraction time (min) 
35 
 






(ng/mL) slope intercept R2 
Buprenorphine 5-100 5 0.1249 -0.0517 0.9921 
Codeine 5-100 5 0.1316 -0.0790 0.9912 
Diazepam 5-100 5 0.1539 -0.0716 0.9928 
Fentanyl 1-100 1 0.0944 -0.0418 0.9968 
Lorazepam 5-100 5 0.0172 0.0285 0.9807 
Nordiazepam 1-100 1 0.2284 -0.2942 0.9818 
Oxazepam 10-100 10 0.1000 -0.0004 0.9976 
Propranolol 5-100 5 0.1148 -0.0418 0.9908 
 
Table 2.11 Precision and Accuracy for Drugs of Abuse Extracted from Small Volumes of Plasma 
by SPME-PESI-MS/MS 
Compound Intra-day Precision (%) Inter-day Precision (%) Accuracy (%) 
  Low  Middle High Low  Middle High Low  Middle High 
Buprenorphine BQL 8 9 BQL 8 12 BQL 90 103 
Codeine BQL 14 7 BQL 6 8 BQL 96 101 
Diazepam BQL 6 10 BQL 6 8 BQL 91 107 
Fentanyl 4 3 2 4 3 4 93 94 105 
Lorazepam BQL 13 13 BQL 16 12 BQL 122 105 
Nordiazepam 9 4 6 8 11 8 96 89 98 
Oxazepam BQL 9 11 BQL 13 27 BQL 87 99 
Propranolol BQL 3 2 BQL 3 5 BQL 93 100 
BQL is below quantifiable level.  









2.4. Conclusion and Future Perspective 
 
 The presented section shows the development of SPME-PESI in three major sections. The 
first section is proof that the coating procedure for the coated PESI probes is reproducible based 
on the low RSDs for intra- and inter-probe reproducibility. In second section the technique of 










Concentration [ng mL-1] 
Figure 2.5 Calibration curves from extracting drugs of abuse from small samples of plasma 
followed by analysis by SPME-PESI-MS/MS (A) Buprenorphine (B) Codeine (C) Diazepam (D) 
Fentanyl (E) Lorazepam (F) Nordiazepam (G) Oxazepam (H) Propranolol 
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investigation explored which desorption solvent gives the best signal and the factors that influence 
these. The second investigation was to prove that SPME-PESI-MS/MS depletes the extracted 
probe and to explore why the ion chromatogram resembles the shape of a decay curve. The third 
investigation was to prove if SPME-PESI-MS/MS can be used to construct calibration curves. 
Afterwards SPME-PESI-MS/MS was used to analyze drugs of abuse from small volumes of 
plasma without any additional pre-treatment steps. Linearity measured by R2 values exceeded 
0.9900 for 6 of the 8 drugs of abuse and for the remaining 2 drugs of abuse R2 values above 0.9800 
was observed. LOQ obtained for fentanyl and nordiazepam were 1 ng mL-1, while the LOQ 
obtained for buprenorphine, codeine, diazepam, lorazepam, and propranolol were 5 ng mL-1, and 
the LOQ obtained for oxazepam was 10 ng mL-1.  
Further development of SPME-PESI-MS/MS can make it an ideal technique for clinical 
applications where minimal invasiveness is required or only extremely small sample volumes can 
be collected. These devices can be ideal tools for application like in-situ analysis and single cell 
analysis of plants and animals due to its smaller dimensions, where preconcentration by 
conventional sample preparation techniques is not possible due to limited sample volume. The 
rapid mass spectrometry determinations of extracted samples by SPME-PESI-MS/MS can make 
it an attractive technique in areas such as prenatal high throughput screening using multi-well 
parallel extraction.53,61 The small dimensions of the coated PESI probes may lead to non depletive 
extraction from small volumes of sample such that free concentrations of analytes and binding 










An important pharmacokinetic/pharmacodynamic parameter that is commonly quantified 
is plasma protein binding (PPB).63 PPB is the binding of a drug to plasma proteins.64 Two major 
constituents of human plasma known for binding pharmaceuticals in an unspecific manner are 
human serum albumin and α1-acid glycoprotein. Other constituents of plasma such as lipoproteins 
play a role in PPB, but have not been investigated to the same depth as the aforementioned 
constituents in literature.65 PPB plays a major role in determining a drug’s effect on the body by 
influencing the free concentration of said drug which in turn influences its clearance and/or 
concentration available for binding with target receptors.66 Biological differences between persons 
and even within the same person can shift the free concentration or PPB of a drug. 67–69 For drug 
with a narrow therapeutic range this shift can lead to detrimental effects which are not reflected by 
total concentration measurements.70,71 In addition therapeutic agents may not have a constant PPB 
which is assumed when using total concentration measurements for therapeutic drug monitoring 
(TDM).70 Ideally free concentration would be used in TDM due to a better correlation with a drug’s 
therapeutic effect compared to the drug’s total concentration.71 
The quantification of PPB is commonly conducted using equilibrium dialysis (ED), and 
ultrafiltration. ED is considered the gold standard for PPB measurements, and is based on the 
partitioning of the analyte between plasma and buffer that is separated by a semi-permeable 
membrane.64 Once partitioning of the analyte reaches equilibrium, the free concentration can be 
determined.64 Disadvantages to ED are labour intensity, long equilibrium times for some 
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compounds, the possibility of Donnan effects, and the analyte possibly binding to the 
semipermeable membrane.72  Alternatively, ultrafiltration uses a device containing upper and 
lower chambers separated by a membrane with a specific molecular cut-off to separate the unbound 
fraction of an analyte by centrifugation. During centrifugation, the unbound fraction passes 
through the membrane into the lower chamber while the bound fraction is unable to pass through 
the membrane, and is retained in the upper chamber.64 Ultrafiltration has several advantages over 
ED, specifically that it is faster and less labour intensive than ED.64 However, errors in the 
calculated PPB from ultrafiltration arise when there is nonspecific binding to the membrane, and 
potential leakage of plasma protein through the membrane.65 
An alternative to ED and ultracentrifugation for measuring the PPB is SPME. SPME is a 
microextraction technique where analytes partition between a relatively small amount of sorbent 
attached to a solid support and the sample.18 This in turn means that SPME only extract the free 
fraction of analytes.22 Therefore the microextractive nature of SPME allows for the accurate 
determination of analyte free concentration from a sample provided the extraction is non-
depletive.22 Literature points to several examples in which SPME was used to determine either the 
PPB and/or free concentration of analytes.62,73–75 Musteata, et al., determined the PPB of 
ibuprofen, warfarin, verapamil, propranolol, and caffeine with SPME.73 Ferguson, et al., 
investigated the limitations of equilibrium dialysis by comparing PPB calculated by rapid 
equilibrium dialysis (RED) and SPME.74 The results show that certain environmental chemicals 
used did not reach equilibrium by RED while PPB for those chemicals were determined by 
SPME.74 PPB measurements by SPME can be conducted on chemicals with a wider range of 
physiochemical properties than RED, as reported by Ferguson et al.74 The PPB of di-2-
pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC), an anti-cancer drug that 
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chelates and has nonspecific binding to several common filtration membranes was determined by 
SPME by Reimerová et al using SPME.75 The SPME devices in this study consisted of a silicon 
string support coated with C18 particles and a polydimethylsiloxane binder to avoid the 
nonspecific binding issues that conventional methodologies had with DpC.75 Research has also 
demonstrated that a 96 well plate format of SPME can be automated to decrease labour associated 
with a workflow.61  
Musteata commented that the incremental progress of free concentration measurements for 
TDM were in part due to the speed and affordability advantages that total concentration 
measurements have.71 To increase the adoption of free concentration measurements for TDM the 
speed and affordability of SPME based free concentration measurements can be pushed further. 
One method is to use SPME based AIMS techniques as the lack of chromatography can increase 
speed and affordability. A recent study by Rickert et al. highlighted the use of CBS as a promising 
alternative for the TDM of the total concentration of four immunosuppressants.54 In a similar 
manner SPME-PESI-MS/MS can be a promising technique for free concentration based TDM. 
This chapter demonstrates a proof of concept for obtaining free concentration or PPB by 
SPME-PESI-MS/MS. The rationale behind using this technique is two-fold. The first reason is that 
other SPME based AIMS techniques for example CBS uses a much larger extraction phase which 
would disturb the equilibrium between the drug and the matrix.76 The volume of sample needed 
for most SPME based AIMS techniques to extract negligible amounts of a therapeutic agent (under 
1% recovery) is generally not practical for clinical cases.77 In the case of SPME-PESI-MS/MS the 
coating is relatively small therefore less likely to deplete the target drug from the sample based on 
previous studies.76 Secondly the use of nano-ESI emitters to couple small SPME fibers directly to 
a MS is prone to the possibility of clogging.30 SPME-PESI-MS/MS on the other hand is not prone 
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to clogging. The measurement of PPB by any AIMS techniques was not reported in publication 
yet during the writing of this thesis. 
3.2. Materials and Method 
 
3.2.1 Chemicals and materials 
 
LC-MS grade ACN, IPA, MeOH, and H2O were purchased directly from Fisher Scientific 
(Bartlesville, OK, USA). FA, sodium chloride, potassium chloride, potassium phosphate 
monobasic, sodium phosphate dibasic, hydrochloric acid, HPLC grade MeOH were purchased 
from Sigma Aldrich (Oakville, ON, Canada). The following chemical were purchased from Sigma 
Aldrich (Oakville, ON, Canada) specifically for the synthesis of 1.3µm HLB particles; 
divinylbenzene, N-vinylpyrrolidone, and 2,2-Azobis(isobutyronitrile). Diazepam and diazepam-
d6 were purchased from Cerilliant Corporation (Round Rock, TX, USA). Frozen, pooled gender, 
non-filtered human plasma with K2EDTA as the anticoagulating agent was purchased from 
Bioreclamation IVT (Westbury, NY, USA). PESI probes and sample plates were kindly donated 
by Shimadzu Corporation (Kyoto, Japan).  
 Methanolic working standards were prepared from the stock solutions of diazepam and 
diazepam-d6. Plasma and PBS samples were spiked such that no more than 1% organic working 
standard was added. This was done to ensure that no alterations occurred in the matrix that can 
measurably affect either the equilibrium constant between the coated probe and the sample or the 
plasma protein binding of the analyte.19,62 Working standards were stored in -80 ˚C. All plasma 
samples when spiked with analytes, and then incubated at 4 ˚C for a minimum of 12 hours to allow 
for adequate binding with the plasma. 
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 The HLB synthesis procedure and PBS preparation procedure from the supplemental 
information of Vasiljevic et al. was followed.58,59 An in-house built stage equipped with a motor 
(MTS50/M-Z8E, 50 mm) from ThorLabs Inc. (Newton, MA, USA) was used for dip coating the 
PESI probes. A VWR Thermal Shake Touch benchtop agitator was used when maintaining a 
temperature of 37 ˚C during static extractions. Before extractions, spiked plasma or PBS samples 
were heated to 37˚ for 30 min with no agitation with the benchtop agitator. 
3.2.2 LC-MS/MS Instrumentation and Method 
 
See section 2.2.2 for the LC-MS/MS instrumentation and method, the only modification 
is that only transitions for diazepam and diazepam-d6 were used. 
3.2.3 SPME-PESI-MS/MS Instrumentation and Method 
 
See section 2.2.3 for the SPME-PESI-MS/MS instrumentation and method, the only 
modification is that only transitions for diazepam and diazepam-d6 were used. 
3.2.4 Preparation of Coated PESI probes 
 
See section 2.2.4 for the coating procedure for the PESI probes. 
3.2.5 Extraction Time Profiles 
 
 ETPs of coated PESI probes in PBS or plasma were determined by the static extraction of 
1.5mL aliquots of sample spiked with 10 ng mL-1 of diazepam held at 37˚C for the following time 
points in triplicates: 10, 30, 45, 60, 75, and 90 min. Following the extraction, the probes were 
rinsed for 3s with H2O, and then statically desorbed for 30 min in 50µL MeOH/ACN (v/v 4/1). 
The extracts were then analyzed by LC-MS/MS. PPB was calculated using the equation below 
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𝑃𝑃𝐵 = (1 −  
[𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑝𝑙𝑎𝑠𝑚𝑎]
[𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑓𝑟𝑜𝑚 𝑃𝐵𝑆]
) ∗ 100       (5)  
3.2.6 Calibration Curves for determination of PPB 
 
 A calibration curve with IS correction and a weighting of 1/x was constructed using the 
following concentrations of diazepam spiked in 1.5 mL aliquots of PBS (n = 5): 0.05, 0.1, 0.25, 1, 
5, 10, and 25 ng mL-1 using a 60 min static extraction at 37°C. Aliquots of 1.5mL plasma spiked 
with 25 ng mL-1 diazepam (n = 5) were also analyzed using the above extraction conditions. After 
extraction, a 3s rinse with H2O was conducted followed by air drying. The dried probes were used 
for SPME-PESI-MS/MS using 10µL of IPA/H2O (v/v 1/1) + 0.1% FA. The calibration curve 
constructed from PBS extracts was used to calculate the free concentration of diazepam from the 
plasma sample using equation (5). 
3.3 Results and Discussion 
 
3.3.1 LC-MS/MS Confirmation of PPB 
 
 Before starting any experiments with SPME-PESI-MS/MS, the capability of the coated 
PESI probes to measure the PPB of diazepam from human plasma was evaluated by LC-MS/MS.  
ETPs for PBS and plasma were constructed from the LC-MS/MS experiments as shown in Figure 
3.1. Based on Figure 3.1(A), the equilibrium time for static extraction of diazepam from PBS at 
37 ˚C was approximately 60 min. The equilibrium time for the static extraction of diazepam from 
plasma at 37 ˚C was approximately 30 min based on Figure 3.1(B). The recovery of diazepam 
from PBS and plasma were determined by dividing the ng extracted by the coated PESI probe at 
the 60 min time point calculated using an instrumental calibration curve by the ng of diazepam 
spiked into the sample. The recovery of diazepam from PBS and plasma at 60 min were 0.90% 
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and 0.015% respectively. This is under the 1% recommended recovery limit to prevent depletion 
of the sample.77,78 Depletion of the analyte from the sample can result in changes to the “true” 
equilibrium between the free and bound concentrations of analytes in the matrix. This will 
ultimately lead to an incorrect determination of the PPB because the new equilibrium will not 
reflect the actual free concentration and PPB. The PPB of diazepam obtained by LC-MS/MS 
analysis was 98.4±0.5%, 98.2±0.2%, and 98.4±0.2% for the time points 60, 75, and 90 min, 
respectively. This was calculated by equation (3) using concentrations of extracted diazepam 
calculated from an instrumental calibration. When compared to literature values, there is close 
agreement, with reported PPBs ranging from 97 – 99% in human plasma.64,67,79–81 Therefore 
capability of determining PPB by the coated PESI probes were confirmed by LC-MS/MS from 




Figure 3.1 Extraction time profile of diazepam in (A) PBS (B) plasma. 
 
3.3.2 Calibration Curve and Comparison of PPB Comparison of Values 
 
The calibration curve constructed by SPME-PESI-MS/MS (Figure 3.2) by extracting 
spiked PBS with diazepam was used to calculate a PPB of 99.3 ± 0.2% which was similar to the 
PPB of 98.4±0.5% calculated in the previous section for the same extraction times. The calibration 
curve had a high linearity based on an R2 of 0.9947 and RSDs of <14%. The concentrations of 
diazepam from plasma and PBS used to calculated PPB were calculated using the linear regression 
from Figure 3.2. The PPB calculated for diazepam by SPME-PESI-MS/MS was within the 






Figure 3.2 Calibration curve of diazepam extracted from PBS using SPME-PESI-MS/MS.  
 
3.4 Conclusion and Future Perspectives 
 
 Based on the agreement of the PPB values generated by SPME-PESI-MS/MS and LC-
MS/MS of 99.3±0.2% and 98.4±0.5%, respectively, and its agreement with reported literature 
values of 97-99%.64,67,79–81 Therefore SPME-PESI-MS/MS has been demonstrated to be an 
effective tool for accurately calculating the PPB and determining the free concentration of 
diazepam. Furthermore, this highlights the ability to quantitate PPB by AIMS, which has not been 
reported yet as of the submission of this thesis. The ability to conduct AIMS workflows that can 
determine the free concentration, have high throughput, and have lower workflow times compared 
to LC-MS/MS methods provide an attractive alternative to current therapeutic drug monitoring 
methods that rely on determining total concentration.71 To take the determination of PPB and free 
concentration from the proof of concept demonstrated in this section to a more applicable form for 
applications such as TDM the equilibrium time of samples should be reduced as well as coupled 
































leveraged for TDM directly from relevant tissue in-vivo for more biologically significant 
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aminoglycosides, help with designing several experiments conducted, and interpretation of 
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4.2 Introduction 
 
Aminoglycosides are a class of broad-spectrum antibiotics that inhibit protein synthesis.82 
Aminoglycosides are generally characterized by linking at least two amino sugars via a glycosidic 
bond with an aminocyclitol ring as shown in Figure 4.1.83 These compounds are very hydrophilic, 
highly water-soluble and were among the first antibiotics to be used clinically.82 However, their 
cochleotoxicity, nephrotoxicity, ototoxicity, and vestibulotoxicity led a shift away from their 
prescription towards less toxic antibiotics.84–86 However, in recent years there has been a shift 
towards the increased prescription of aminoglycosides for clinical use due to the rise of multi-
resistant microbes and a better understanding of dosage regimes for aminoglycosides.82,87–89 While 
better dosage regimes help mitigate toxic side effects when used clinically, these compounds are 
also used in widespread practice as veterinary drugs for farm animals. Veterinary drugs are used 
in modern farming practices for treating infection or infection prevention.53 Aminoglycosides as 
veterinary drugs when misused can be found in foodstuff at residual levels. Despite the residual 
levels, the toxicity of aminoglycosides may possess human risk.83 To regulate aminoglycoside 
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misuse as veterinary drugs, different jurisdictions regulate the use of these compounds through 
regulations such as Council Directive 96/23/EC.90  
 
Figure 4.1 Structures of aminoglycosides of interest. 
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Aminoglycosides are non-metabolizable agents and thus a substantial amount of the 
original molecules excreted to the environment by living organisms.83 There are several alternative 
sources like emissions by hospitals or pharmaceutical company, incomplete elimination in sewage 
treatment plants, and extensive abuse in farming and aquaculture are also available that have been 
released considerable amounts of aminoglycosides into the environment.83 Their presence in the 
aquatic environment especially drinking water is considered a potential risk. Therefore, 
aminoglycosides have received great attention towards monitoring their presence in aquatic 
environments and wastewater effluent to ensure the quality of various types of water samples.91–94 
Monitoring the residual level of aminoglycosides in the aquatic environment particularly 
wastewater effluents allows for a better understand regarding the usage of aminoglycosides and 
the rise of aminoglycoside resistance in bacteria.95,96 On the other hand, the monitoring of 
aminoglycosides in the aquatic environment is a challenging task as they are highly hydrophilic 
and water-soluble. The detection, monitoring, and quantification of aminoglycosides in all three 
areas of clinical samples, foodstuff, and water have driven the development of analytical methods 
that are fit for purpose.  
Analytical methods giving reasonable qualitative and quantitative monitoring of multiple 
aminoglycosides are difficult due to the certain combination of properties they possess. The lack 
of a chromophore and fluorophore make certain types of detectors such as UV or fluorescence 
difficult without derivatization steps.97,98 The multiple amino and hydroxyl groups that 
aminoglycosides contain cause high hydrophilicity which also makes it difficult to incorporate into 
multiresidue methods.99–101 This was highlighted in a series of articles published by Desmarchelier 
and colleagues where the determination of aminoglycosides required a completely different sample 
preparation and LC method for proper screening compared to the other veterinary drugs.100,102–105  
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When multiple aminoglycosides are determined by LC-MS the methods tend to use either ion 
pairing or hydrophilic interaction liquid chromatograph (HILIC) for separation.83 The drawbacks 
of using ion pairing reagents are that they are difficult to remove from the LC-MS, usually not 
volatile, cause ion suppression, and containment the ion source.102,106,107 The drawbacks of using 
HILIC columns stem particularly from the use of zwitterionic columns where large concentrations 
of salt are needed in addition to FA for proper separation of aminoglycosides.108 These drawbacks 
include the use of large concentrations of salt leading to salt precipitation, high organic solvent 
percentages which lead to poor solubility of aminoglycosides, and long equilibration times.102,109–
111 Overall the drawbacks to both ion pairing and HILIC in the case of aminoglycoside analysis 
leads to more maintenance of the LC-MS system and reduced operational time. To overcome these 
issues, AIMS can be used as a screening tool to determine the presence of aminoglycosides. The 
lack of chromatography and shorter workflow times leads to a screening method that is more 
economical than LC-MS based screening method as there is no use of high salt concentrations or 
ion-pairing reagents. To ensure proper sensitivity is reached sample preparation is used to 
preconcentrate and extract analyte.  
In this chapter SPME-PESI-MS/MS was developed to qualitatively screen 
aminoglycosides from water. The detection of aminoglycosides by SPME techniques are sparse 
with only two pieces of literature that work with multiple aminoglycosides which are Chen et al. 
and Wang J. et al.112,113 The hydrophilic nature of aminoglycosides demands the use of specialized 
coatings which Chen et al. and Wang et al have produced.112,113 For this study, a nitrogen-rich 
organic polymer was used for the coating of the PESI probes, and various parameters were 






4.3.1 Chemicals and Method 
 
The following LC-MS grade chemicals were purchased from Fischer Scientific 
(Bartlesville, OK, USA): acetone, ACN, IPA, MeOH, and H2O. Reagent grade dimethylsufoxide 
(DMSO) was purchased from Sigma Aldrich. The following chemicals were purchased from 
Sigma Aldrich (Oakville, ON, Canada): acetic acid, FA, hydrochloric acid, LC grade MeOH, N,N-
diisopropylethylamine, potassium phosphate dibasic, potassium phosphate monobasic, sodium 
acetate, sodium bicarbonate, sodium carbonate, and sodium hydroxide. PESI probes and sample 
plates were donated by Shimadzu Corporation (Kyoto, Japan).  
The following solid standards were purchased directly from Sigma Aldrich (Oakville, ON, 
Canada): amikacin, apramycin sulfate salt, dihydrostreptomycin sulfate, hygromycin B, 
gentamicin sulfate salt, kanamycin A sulfate, sisomicin sulfate, spectinomycin sulfate, 
streptomycin sulfate, and tobramycin. Single standard master stocks of the solid standards were 
made in water such that the free base concentration was 2 mg mL-1. The master stocks were stored 
at – 20 ˚C. A working stock of 100 µg mL-1 of aminoglycosides in water was serially diluted from 
the master stocks. It is noted that all standards and samples containing aminoglycosides were 
stored in polypropylene containers to prevent loss of aminoglycosides due to adsorption with 
glass.114 Nitrogen rich polymeric material was provided by Dr. Kanchan Sinha Roy. 
Acetate buffer was prepared by mixing 1.8g of sodium acetate and 4.6mL of acetic acid in 
500 mL of H2O. The pH of the acetate buffer was adjusted to pH 4 by adding additional acetic acid 
dropwise until the desired pH was reached. Potassium phosphate buffer (pH = 6) was prepared by 
mixing 2.4g of potassium phosphate dibasic and 11.8g of potassium phosphate monobasic in 500 
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mL of H2O. The potassium phosphate buffer (pH = 6) was adjusted to a pH of 6 by adding 1.0M 
sodium hydroxide dropwise until said pH was reached. Potassium phosphate buffer (pH = 7) was 
prepared by mixing 9.4g of potassium phosphate dibasic and 6.3g of potassium phosphate 
monobasic in 500 mL of H2O. The potassium phosphate buffer (pH = 7) was adjusted to a pH of 
7 by adding 1.0M sodium hydroxide dropwise until said pH was reached. Potassium phosphate 
buffer (pH = 8) was prepared by mixing 16.3g of potassium phosphate dibasic and 0.89g of 
potassium phosphate monobasic in 500 mL of H2O. The potassium phosphate buffer (pH = 8) was 
adjusted to a pH of 8 by adding 1.0M sodium hydroxide dropwise until said pH was reached. 
Sodium carbonate buffer was prepared by mixing 3.9g of sodium bicarbonate and 5.7g of sodium 
carbonate in 500mL of H2O. The sodium carbonate buffer was adjusted to a pH of 10 by adding 
1.0M sodium hydroxide dropwise until said pH was reached. 
4.3.2 SPME-PESI-MS/MS Instrumentation and Method 
 
See section 2.2.3 for the SPME-PESI-MS/MS instrumentation and method the only 
modification is that the MS transition table below, Table 4.1 was used instead of Table 2.1. 
Table 4.1 Multiple Reaction Monitoring Parameters for Aminoglycosides 











1 Spectinomycin -2.3a 351.2 207.2 -13 -22 -14 
2 Sisomicin -4.3a 448.1 254.2 -11 -24 -18 
3 Gentamycin C1a -4 a 450.1 322.2 -11 -14 -23 
4 Gentamycin C2 -4.6b 464.1 322.2 -11 -15 -23 
5 Tobramycin -5.8 a 468.1 163.3 -14 -25 -17 
6 Gentamycin C1 -4.1b 478.3 322.2 
 
-10 -16 -23 
7 Kanamycin A -6.3 a 485.2 163.2 -10 -25 -11 
8 Hygromycin B -6.4 a 528.0 352.1 -20 -24 -17 
9 Apramycin -6.5 a 540.1 217.2 -20 -26 -15 
10 Streptomycin -6.4 a 582.0 263.2 -22 -32 -19 
11 Dihydrostreptomycin -7.3 a 583.8 263.2 -20 -32 -19 
12 Amikacin -8.6 a 586.1 163.2 -22 -33 -11 
a Drug bank accessed in November 2020 
b PubChem accessed in November 2020 
Pause time and dwell time for all compounds were both 1 msec. 
All compounds used [M+H]+ adduct except for spectinomycin where the [M+H2O+H]+ was used 
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4.3.3 Preparation of Coated PESI probes 
 
 See section 2.2.4 for the coating procedure for the PESI probes. Two modifications from 
the method discussed in detail in Section 2.2.4 were made. First, the use of nitrogen rich polymeric 
material was provided by Dr. Kanchan Sinha Roy instead of the in-house synthesized 1.3µm HLB 
particles. Second, the coating process was repeated until a coating thickness with a radius of 11.5 
µm and a length of 3 mm was achieved instead of a coating thickness of 6.5 µm and a length of 2 
mm. 
4.3.4 Optimization of Screening Conditions 
 
 In all optimization of screening conditions, 750µL of final sample after modifications was 
used for a 90 min static extraction in triplicates. Following the extraction, the probes were dried at 
room temperature. SPME-PESI-MS/MS was conducted using 10µL of IPA/H2O (v/v, 1/1) + 0.1% 
FA as the desorption solvent for pH adjustment and matrix modification experiments. The pH of 
the spiked water samples were adjusted to the pHs; 4, 6, 7, 8, and 10 using the buffer salts as well 
as formic acid or N,N-diisopropylethylamine. The concentration of spiked aminoglycosides in the 
pH modified water samples were 300 ng mL-1 of aminoglycosides. For the matrix modification 
experiments, initially, water was spiked to contain 300 ng mL-1 of aminoglycosides. The spiked 
water was mixed with the following organic solvents: acetone, ACN, DMSO, IPA, and MeOH 
such that the final samples contained a 50/50 split of spiked water and solvent volumetrically. For 
further matrix modification experiments, the water sample spiked with 300 ng mL-1 of 
aminoglycosides was modified with DMSO, IPA, and MeOH in a different volumetric ratios (1/3, 
1/1, and 3/1) to spiked sample.  
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 For the desorption solvent optimization experiments, the spiked water was modified by the 
addition of IPA such that the final sample was 3/1 IPA/spiked water (v/v). After extraction, the 
different compositions of IPA/H2O ((v/v, 4/1), (v/v, 7/3), (v/v, 3/2), and (v/v, 1/1) all containing 
0.1% FA) were tested as desorption solvents to desorb the analytes from the coated PESI probes.  
For the rinsing investigations, water was used as a rinsing solvent using the same matrix 
modification from the desorption solvent optimization. The rinsing was performed immediately 
after extraction for 3s. For the desorption, optimized desorption solvent was used for SPME-PESI-
MS/MS analysis. 
4.4 Results and Discussion 
 
4.4.1 Effect of pH  
 
 The pH of the extraction sample is an important factor for SPME method development, 
especially when extracting from aqueous samples. The reason is that only undissociated or neutral 
analytes are extracted during the SPME process.19 Therefore, the pH with the highest extraction 
efficiency for the coated probes will ensure the largest proportion of the neutral aminoglycosides, 
and result in the highest sensitivity. The pH of the aqueous samples spiked with aminoglycosides 
was adjusted over the range 4–10.  
The pH modification experiments initially conducted used the following buffers; 0.2 M 
acetate buffer (pH = 4), 0.2 M potassium phosphate buffer (pH = 6), 0.2 M potassium phosphate 
buffer (pH = 7), 0.2 M potassium phosphate buffer (pH = 8), and 0.2M sodium carbonate buffer 
(pH = 10). These buffers were spiked with 300 ng mL-1 of the aminoglycosides. After the 90 min 
extraction, signals were not obtained therefore results were not included. This result likely means 
that no aminoglycosides were extracted from the buffered samples. The cause is likely that metal 
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ions from the buffer salt chelate with the aminoglyocsides’ amino and hydroxyl groups.111,115 This 
would then lead to obstruction of the active functional groups of the aminoglycosides that would 
be capable of interacting with the extraction phase, resulting in no extraction of the analytes which 
in turn shows no responses of the analytes.115 The above experiment and associated literature 
referenced also concludes that the addition of the different salt concentrations is a detriment to the 
extraction efficiency of the aminoglycosides in an aqueous medium which is in line with 
literature.112 Therefore, no experiment was examined to check the effect of salts. 
Further pH experiments were performed using an organic acid or base to adjust the pH of 
the sample to the desired levels as inorganic buffer salts proven to be detrimental for the extraction 
of aminoglycosides. The pH of the spiked aqueous samples were adjusted to 4, 6, 7, 8, and 10 
using FA or N,N-diisopropylethylamine accordingly. The 90 min static extractions at the adjusted 
pH values show significant responses for the aminoglycosides. This confirmed the detrimental 
effect of the inorganic salt from the buffers used in the failed pH optimization experiments. The 
results for the effect of varying sample pH are depicted in Figure 4.2, with the responses 
normalized with respect to the condition giving the highest response for an individual compound. 
The results show that the response of all aminoglycosides increased from a pH 4 to pH 6. 
Afterward, there is a slight increase in the responses at pH 7 and 8 except for apramycin. Around 
pH 7 to 8, most aminoglycosides are close to or above the pKa values for their amino groups.116 
Therefore, their respective neutral species populations are higher. Two notable exceptions are 
dihydrostreptomycin and streptomycin. These two aminoglycosides have an a five-fold increase 
when the pH was increased further to pH 10. All other aminoglycosides, on the other hand, have 
a decrease in response when shifting from a pH 8 to 10. This is most likely due to the deprotonation 
of the hydroxyl groups, therefore leading to a decrease in neutral species.112 The pKa values of the 
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amino groups for dihydrostreptomycin and streptomycin tend to be higher compared to other 
aminoglycosides.116 Based on the response a pH range between 6 to 8 is acceptable as it allows for 
adequate extractions of all aminoglycosides except for dihydrostreptomycin and streptomycin. 
Unfortunately, optimizing pH for dihydrostreptomycin and streptomycin will dramatically 
decrease the response for all other aminoglycosides which is not acceptable.   
 
Figure 4.2 pH optimization of aminoglycoside extraction by SPME-PESI-MS/MS. 
4.4.2 Effect of Organic Modifier 
 
Results from the pH experiment suggest that pH adjustment alone is not sufficient to obtain 
reasonable sensitivity for all aminoglycosides from the aqueous sample. An additional parameter 
is required to increase responses for the aminoglycosides. Therefore, based on Wang et al., who 
modified the sample with 50% ACN to increase extraction efficiencies, organic modifiers were 























pH 4 pH 6 pH 7 pH 8 pH 10
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In an aqueous matrix, the polarity and solvation effect of water will negatively affect the 
overall extraction efficiency of aminoglycosides. Therefore, to investigate the effect of these two 
factors simultaneously and to overcome these effects, different water-miscible organic solvents 
were used as modifiers. An equal volume of the following organic solvents; acetone, ACN, IPA, 
MeOH, and DMSO were mixed with equal volumes of water already spiked with 300 ng mL-1 of 
aminoglycosides.  The extraction efficiency of these water-modified matrices was compared with 
the unmodified spiked water matrix. The results are shown in Figure 4.3. Despite having a final 
concentration of 150 ng mL-1, the modified water matrices tend to show responses similar or higher 
to the unmodified water matrix which having a final concentration of 300 ng mL-1. 
It is evident from the Figures 4.3(A) that ACN and MeOH, both of which are polar solvents, 
gave a significant increase in the instrumental response for all of the analytes of interest.117 This 
could be attributed to the fact that both organic modifiers lower the polarity and solvation effect 
of the aqueous sample (H2O has a polarity of 10.2), ultimately enhancing the extraction 
efficiency.117 To some extent, MeOH shows better responses than ACN as a modifier. The 
response of the MeOH modified sample with an aminoglycoside concentration of 150 ng mL-1 is 
comparable to the unmodified aqueous matrix having aminoglycoside concentration of 300 ng mL-
1. This indicates that extraction efficiency is enhanced either by MeOH lowering the polarity of 
water or by MeOH being a protic solvent and having the ability to break the solvation cage between 





Figure 4.3 Matrix modification investigation (A) ACN & MeOH (B) IPA & MeOH (C) Acetone 




To investigate the effect of polarity and solvation closer, another protic solvent, IPA was 
evaluated as a potential modifier. The response between IPA and MeOH as modifiers were 
compared in Figure 4.3(B). The polarity index of IPA and MeOH are 3.9 and 5.1 respectively.117 
The responses of analytes show an increase when using IPA as the modifier compared to MeOH. 
Being a protic solvent, both modifiers have similar abilities to break the solvation cages, however 
the lower polarity of IPA lowers the affinity of aminoglycosides to the matrix. This, in turn, leads 
to a higher extraction efficiency for the IPA modified sample. 
To further understand the role of modifiers, aprotic solvents like acetone, and DMSO were 
used. Both solvents are structurally similar, with the primary difference being the sulfur in DMSO 
substituted with a carbon for acetone which leads to different polarities. The polarity index of 
DMSO and acetone are 7.2 and 5.1 respectively.117 The responses in Figure 4.3(C) of the analytes 
generally showed a significant increase when using DMSO as the modifier compared to acetone. 
DMSO cannot lower the polarity of the sample to the same extent as acetone, based on the polarity 
index. Instead, DMSO is a well-known solvent for the breaking of a hydrogen bond and 
solvation/hydration sphere.118 This result indicates that DMSO enhances extraction efficiency may 
be primarily by breaking the hydration sphere instead of lowering the polarity.118 
The above experimental evidence suggests both polarity and solvation/hydration have 
significant effects on the extraction of the aminoglycosides from water. This has further evidence 
by comparing analytes response when acetone or MeOH are used as modifiers in Figure 4.3(D). 
Both solvents have a polarity index of 5.1.117  However, MeOH modified samples tend to show a 




Considering the above results and discussion, it is clear that both solvation and polarity are 
influential factors and are simultaneously affecting the extraction of aminoglycosides from 
aqueous samples. Thus, selecting an appropriate matrix modifier is critical for enhancing the 
performance of the assay. Further optimizations were performed to obtain an optimal composition 
of modifiers for the screening aminoglycosides by SPME-PESI/MS/MS. These experiments 
investigated the response of different proportions of DMSO, IPA, and MeOH used to modify the 
spiked water sample, and better understand how the proportions of modifier solvent to spiked water 
samples would positively or negatively impact the extraction of aminoglycosides from water. It is 
evident from Figure 4.4 that the quantity of organic modifiers also has a significant impact on the 
extraction of aminoglycosides. The response of the analytes tends to increase with the quantity of 
organic modifiers. When the water samples were modified with 3 equivalents of organic solvents, 
the analytes responses tend to be higher compared to unmodified water sample (300 ng mL-1) 
despite the concentration of the analytes being a quarter of the concentration of the unmodified 
samples. Based on the results in Figure 4.4 and considering the decrease in polarity and disruption 
of the solvation sphere around the aminoglycosides, IPA was selected as a suitable modifier over 
other organic solvents. Using 3 equivalents of IPA as the modifier gave the best results for 
dihydrostreptomycin, streptomycin, and spectinomycin which had the lowest responses of the 
aminoglycosides which factored heavily into this decision. DMSO was discarded as it is not being 
compatible with MS systems and it has a high boiling solvent, leading to long drying times before 






Figure 4.4 Extended Matrix Modification of Water to Enhance Aminoglycoside Extraction (A) 
Amikacin (B) Apramycin (C) Dihydrostreptomycin (D) Hygromycin B (E) Gentamycin C1 (F) 
Gentamycin C1A (G) Gentamycin C2 (H) Kanamycin A (I) Sisomicin (J) Spectinomycin (K) 
Streptomycin (L) Tobramycin 
 
4.4.3 Effect of Desorption Solvent 
 
 The optimization of desorption solvent is a critical component for SPME-PESI-MS/MS as 
the desorption solvent must balance the following factors: optimum desorption of the analytes 
from the coating, the amount of desorption solvent loaded onto the coated PESI probe from the 
sample plate by the picking process, and the compatibility with the ESI process. Based on the 
results in Figure 4.5, the optimal desorption solvent was determined IPA/H2O (v/v 3/2) + 0.1% 
FA. This desorption solvent gave the best response overall especially for the aminoglycosides that 
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tended to give lower responses. The FA plays a pivotal role for desorption as it should be noted 
that the extraction matrix was composed of IPA/H2O (v/v 3/1). The mechanism of desorption 
hinges on the acidic desorption solvent protonating the amino groups of the aminoglycosides 
leading to the disruption of the interactions between the coating and analytes. 
 
Figure 4.5 Optimization of Desorption Solvent for Aminoglycosides by SPME-PESI-MS/MS. 
 
4.4.4 Effect of Rinsing 
 
 The effect of rinsing before the desorption/ionization step on the response produced by the 
SPME-PESI-MS/MS was investigated using water as rising solvent. This investigation was 
conducted to check whether the aminoglycosides would remain onto the coating after a rinsing 
step or not. The results of this investigation are compiled in Figure 4.6. The results show that 
rinsing with water did not show any significant decrease in signal when compared to no rinsing. 
This provides evidence that the aminoglycosides were strongly bound onto the coating of the 






























Figure 4.6 Investigation of the Effect of Rinse Solvents. 
4.5 Conclusion and Future Perspectives 
 
 In this work, the qualitative screening parameters like different extraction and desorption 
conditions of aminoglycosides were investigated for SPME-PESI-MS/MS. It was found that a pH 
range between 6 – 8, with no salt, and the addition of IPA as an organic modifier gave optimal 
responses. The optimal desorption solvent found was IPA/H2O (v/v 3/2) + 0.1%FA. Based on 
these parameters, the 12 aminoglycosides spiked in water were able to be screened. Future 
experiments to investigate the ability of this method to quantitate aminoglycosides include an ETP 
and a calibration curve. The ability to quantify these analytes by SPME-PESI-MS/MS can be 
characterized further with more complex matrices such as food stuffs and clinical samples. In a 
more broader context, the work done in this chapter demonstrates the future of SPME based 
technologies to target more polar compounds with novel coatings and the use of AIMS technology 
for screening methods in place of LC-MS based screening that use LC conditions which are not 



























No Rinse Rinse With Water
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Chapter 5 Conclusion and Looking Forward  
 In conclusion, SPME-PESI-MS/MS is a novel method to incorporate SPME as a sample 
preparation method to an already commercial PESI-MS system. Unlike previous mentions of 
literature using SPME-PESI, this variant of SPME-PESI uses commercial PESI probes which are 
120 µm in diameter. This leads to the use of a pick and spray method for desorption and 
subsequently ionization. In chapter 2 several underlying aspects behind SPME-PESI-MS/MS was 
explored and then SPME-PESI-MS/MS was applied to 30µL plasma samples. The underlying 
aspects explored included the reproducibility of coating the probe, why the chromatograms of 
SPME-PESI-MS/MS look reminiscent of decay curves, and factors that influence the optimal 
desorption solvent. In chapter 3 the small dimensions of the coated probes were leveraged to 
perform free concentration and PPB measurements of diazepam from human plasma. Ultimately 
a PPB of 99.3±0.2% was derived from a sample of human plasma spiked with 25 ng mL-1 of 
diazepam. This makes it the first public reporting of AIMS technology quantitating PPB. In chapter 
4 the use of SPME-PESI-MS/MS for the detection of aminoglycosides was explored by optimizing 
factors increasing the extraction efficiency. It was noted that controlling pH, salt concentration, 
and adding organic modifier are important when extracting aminoglycosides using SPME-PESI-
MS/MS. 
 Looking forward there are many exciting aspects about SPME-PESI-MS/MS to be 
explored. The more basic aspects of SPME-PESI-MS/MS need to be investigated in greater depth. 
Different desorption solvent compositions and how their various physical properties effect the 
overall desorption and ionization process including tertiary mixtures as desorption solvents. 
Furthermore, a more in-depth study into how the desorption volume affects response should be 
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conducted while isolating these effects from the increased ionization efficiency from the small 
initial droplet size generated by PESI systems. The ability to agitate the coated probes are another 
important aspect to explore as orbital rotation used initially was found to be irreproducible. 
Expanding the use of SPME-PESI-MS/MS and AIMS in general in the arena of free concentration 
will be exciting and would hopefully lead to TDM that use more therapeutically relevant 
measurements. The exploration of extracting aminoglycosides by SPME-PESI-MS/MS hopefully 
provides a way forward for future alternative AIMS screening methods to current LC based 
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